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ABSTRACT
Bioinformatic Study of γ-Secretase and its Substrates
Fei Nan
γ-Secretase is an enzymatic complex critical to amyloid formation and other important
pathophysiological processes. Non-specific γ-secretase inhibitors are not ideal for
intervention of familial Alzheimer’s disease. The four essential include Presenilin (PS1 or
PS-2), APH-1, Pen-2, nicastrin (Nct). Also γ-secretase cleaves a variety of substrates
(over 30). But different sites are cleaved even in a single substrate and no consensus
sequence for cleavage by γ-secretase is identified. We hypothesize that consensus
compositional sequence (or functional domain) in components of γ-secretase and/or its
substrates should exist during γ-secretase regulation and specific γ-secretase inhibitor
based on such consensus sequence (or functional domain) may act as a therapeutic
intervention for familial Alzheimer’s disease. We divide our research into two stages. At
Stage I, we find the candidates by the methods of bioinformatics. The less, the better. By
using the resources of genetic and protein databases and tools, selecting software to apply
sequence analysis, modeling and simulation, and pattern recognition of γ-secretase
regulation, we identify candidates of consensus sequences (or functional domains). At
Stage II, we use the traditional biological methods to verify the critical role of the
candidates including the protein purification, recognition, and functional domain
interaction. This thesis work is particularly focused on Stage I.
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1. Introduction

1.1 Alzheimer’s Disease and Amyloid-β
Alzheimer's disease is a neurodegenerative disease that, in its most common form, is
found in people over age 65. Approximately 24 million people worldwide have dementia
of which about 60% is due to Alzheimer's disease.

Figure 1. Histopathologic image of senile plaques seen in the cerebral
cortex in a patient with Alzheimer’s disease of presenile onset. Silver
impregnation.

Plaques which contain misfolded peptides called amyloid-β (Aβ) are formed in the brain
many years before the onset of Alzheimer's disease. Together, these plaques and
neurofibrillary tangles form the pathological signs of the disease. These features can only
be discovered at autopsy and help to confirm the clinical diagnosis. Medications can help
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relieve the symptoms of the disease, but evidence proves that they canot change the
course of the underlying pathology.

Experimental and genetic evidence has indicated that amyloid-β (Aβ) plays an essential
role in the Alzheimer’s disease pathogenesis. The malicious protein aggregates in the
brain hippocampus and brain cortex of the patients of Alzheimer’s disease as well as selfaccumulation to form malicious oligomers which will cause neurodegeneration. Genetic
defects identified include mutations in the Presenlin 1 gene on chromosome 14, the
Presenilin 2 gene on chromosome 1, and the amyloid precursor protein (APP) gene on
chromosome 21.

Alzheimer's disease has been identified as a protein misfolding disease due to the
accumulation of abnormally folded amyloid-β (Aβ) in the brains of Alzheimer's disease
patients (Hashimoto et al 2003). Amyloid-β (Aβ) is a short peptide that is a proteolytic
byproduct of the transmembrane protein amyloid precursor protein (APP), whose
function is unclear but thought to be involved in neuronal development (Rudolph et al
2000). Although Amyloid-β (Aβ) monomers are soluble and harmless, they undergo a
dramatic conformational change at sufficiently high concentration to form a beta sheetrich tertiary structure that aggregates to form amyloid fibrils (Ohnishi et al 2004) that
deposit outside neurons in dense formations known as senile plaques or neuritic plaques,
in less dense aggregates as diffuse plaques, and sometimes in the walls of small blood
vessels in the brain in a process called amyloid angiopathy or congophilic angiopathy.

Recent research includes hypotheses centered on the effects of the misfolded and
aggregated proteins, amyloid-β (Aβ) and amyloid-τ (Aτ). The τ hypothesis is supported
by the long-standing observation that deposition of amyloid plaques do not correlate well
with neuron loss (Mudher et al 2002). However, a majority of researchers support the
alternative hypothesis that Aβ is the primary causative agent (Schmitz et al 2004).
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1.2 Secretase
Secretases are enzymes that cut pieces off a longer protein that is embedded in the cell
membrane. There are three types of components for secretase, namely α-secretase, βsecretase and γ-secretase.

Figure 2. Amyloid-β is created from amyloid precursor protein, through
two sequential proteolytic cleavages where secretases act on the amyloid
precursor protein (APP) to cleave the protein into three fragments.
Sequential cleavage by β-secretase (BACE) and γ-secretase produces the
amyloid-β (Aβ) peptide fragment that aggregates into plaques in the brains
of Alzheimer's disease patients.

Amyloid-β is heterogenous and formed from the precursor protein, called amyloid
precursor protein, through two sequential proteolytic cleavages that involve β-secretase
and γ-secretase. Specifically speaking, secretases act on the amyloid precursor protein
(APP) to cleave the protein into three fragments. Sequential cleavage by β-secretase
(BACE) and γ-secretase produces the amyloid-β (Aβ) peptide fragment that aggregates
into clumps called "plaques" in the brains of Alzheimer's disease patients. If α-secretase
acts on amyloid precursor protein (APP) first instead of β-secretase (BACE), no amyloid-
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β (Aβ) is formed because α-secretase recognizes a target protein sequence closer to the
cell surface than β-secretase (BACE). The non-pathogenic middle fragment formed by an
α-secretase and γ-secretase cleavage sequence is referred to as P3.
However, together with β-secretase, γ-secretase will cleave the amyloid precursor protein
by creating peptides of various lengths, namely Aβ40 and Aβ42. The longer one of Aβ40
and Aβ42 is more aggregating than the other one. The ratio of Aβ42 over Aβ40 is
increased by familial Alzheimer’s disease mutations occurring in the presenilin genes or
in amyloid precursor protein, near the γ-secretase cleavage site. Thus, γ-secretase is able
to determine the solubility of the created Aβ fragment and attract a wide popular attention
in pharmaceutical drug industry.
The structure of the three secretases varies widely. The α-secretase gene has not been
conclusively identified but is believed to be a metalloproteinase. β-secretase (BACE) is a
transmembrane protein with an extracellular aspartic acid protease domain.
γ-secretase is an integral membrane protein, that cleaves single-pass transmembrane
proteins at residues within the transmembrane domain. It is a protein complex containing
presenilin, nicastrin, ACH-1, and PEN-2 and its biological mechanism remains under
extensive research interests. Presenilin is believed to harbor the protease domain and
represents an important example of a rare type of protease that cleaves targets within the
cell membrane.
Several successful γ-secretase inhibitors have been discovered by screening drug libraries
and designing aspartyl protease transition-state analogues based on the amyloid precursor
protein (APP) substrate cleavage site. Most of these compounds are very general, not
specific enough for γ-secretase cleavage site of amyloid precursor protein (APP), and
equally inhibit the processing of other γ-secretase substrates, such as Notch and other
cell-surface proteins and receptors involved in embryonic development, haematopoiesis,
cell adhesion and cell/cell contacts.
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Thus, it’s more desirable for research scientists to focus on finding compounds that show
selectivity for amyloid precursor protein (APP) cleavage and particularly inhibit the
formation of the aggregating form of Aβ42. Compounds that target the substrate docking
site instead of the enzyme active site could be another featured point worth of
investigation as an alternative strategy. The finding that some NSAID analogues
preferentially inhibit the formation of Aβ42 over Aβ40 and do not affect Notch
processing has opened a new therapeutic window. The progress in design of selective
inhibitors as well as recent results obtained in animal studies prove that γ-secretase
remains among the best targets for the therapeutic control of amyloid build-up in
Alzheimer’s disease. The full understanding of γ-secretase regulation may yet uncover
new therapeutic interests.

Besides the involvement in the pathogenesis of Alzheimer's disease, these proteins also
have other functional roles in the cell. γ-secretase plays an essential role in developmental
signalling by the transmembrane receptor Notch, freeing the cytoplasmic tail of Notch to
travel to the cell nucleus to act as a transcription factor. Although β-secretase (BACE)
cleaves the extracellular domains of several transmembrane proteins, its physiological
function remains unknown.

1.3 Contributions
Many biochemists and biological scientists have tried to narrow down a way to determine
the γ-secretase cleavage site mechanisms based on their primary, secondary, tertiary and
quaternary structures. In this thesis, we are able to determine the consensus compositional
sequences or functional domain of γ-secretase and its substrates as a possible therapeutic
intervention. Then, we find the candidates of consensus sequence and functional domain
by the methods of bioinformatics and collaborate to use traditional biological methods to
verify the critical role of candidates including protein purification, recognition and
domain functional interaction.
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We also hope that we can apply the sequence comparison techniques and identify the
candidate motifs and domains for all components of γ-secretase and its substrates.
Meanwhile, we plan to biologically knockout and verify the functionality of those
identified motifs and domains including protein purification, recognition and interaction.
Finally we evaluate the efficacy of the bioinformatics tools and cast the direction of
prospective improvements.

1.4 Organization
The thesis is organized as follows; Chapter 1 gives an overall introduction. Chapter 2
reviews the literature and related work. We present the typical genetic structures. Then,
we go over the current methods in γ-secretase identification. Then, we describe the
relation among amyloid-β (Aβ) and γ-secretase. Chapter 3 presents our primary
methodology. We describe the bioinformatics approach to obtain the motifs and domains
for amyloid-β (Aβ) and γ-secretase. We give evidence for the idenfitication. Chapter 4
presents the results of the application of our methodology. We conclude the thesis with a
summary of the proposed work and future directions in Chapter 5.
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2. Literature Review

2.1 Alzheimer’s Disease hypothetic mechanisms
There are three major competing hypotheses on the possible cause of the Alzheimer’s
disease. The oldest, on which most currently available drug therapies are based, is known
as the "cholinergic hypothesis" and suggests that Alzheimer’s disease is due to reduced
biosynthesis of the neurotransmitter acetylcholine. The medications that treat
acetylcholine deficiency have served to only treat symptoms of the disease and have
neither halted nor reversed it (Walker et al 2006). The cholinergic hypothesis has not
maintained widespread support in the face of this evidence, although cholingeric effects
have been proposed to initiate large-scale aggregation (Shen 2004) leading to generalized
neuroinflammation (WenK 2006).

Recent research includes hypotheses centered on the effects of the misfolded and
aggregated proteins, amyloid-β and amyloid-τ. The two positions differ, with one stating
that the amyloid-τ protein abnormalities initiate the disease cascade, while the other states
that amyloid-β (Aβ) deposits are the causative factor in the disease (Mudher et al 2002).
The amyloid-τ hypothesis is supported by the long-standing observation that deposition
of amyloid plaques do not correlate well with neuron loss (Schmitz et al 2004). However,
a majority of researchers support the alternative hypothesis that amyloid-β (Aβ) is the
primary causative agent (Mudher et al 2002).

The amyloid hypothesis is initially compelling because the gene for the amyloid
precursor protein (APP) is located on chromosome 21, and patients with trisomy 21
(Down Syndrome) who thus have an extra gene copy almost universally exhibit
Alzheimer’s disease-like disorders by 40 years of age (Nistor et al 2006, Lott et al 2005).
The traditional formulation of the amyloid hypothesis points to the cytotoxicity of mature
aggregated amyloid fibrils, which are believed to be the toxic form of the protein
responsible for disrupting the cell's calcium ion homeostasis and thus inducing apoptosis
7

(Yankner et al 1990). A more recent and widely supported hypothesis suggests that the
cytotoxic species is an intermediate misfolded form of amyloid-β (Aβ), neither a soluble
monomer nor a mature aggregated polymer but an oligomeric species (Blanchard et al
2000). Relevantly, much early development work on lead compounds has focused on the
inhibition of fibrillization (Blanchard et al 2004, Porat et al 2006, Kanapathipillai et al
2005), but the toxic-oligomer theory would imply that prevention of oligomeric assembly
is the more important process (Lee et al 2005) or that a better target lies upstream, for
example in the inhibition of amyloid precursor protein (APP) processing to amyloid-β
(Aβ) (Espeseth et al 2005).

It should be noted further that ApoE4, the major genetic risk factor for Alzheimer’s
disease, leads to excess amyloid build up in the brain cortex and hippocampus before
Alzheimer’s disease symptoms arise. Thus, amyloid-β (Aβ) deposition precedes clinical
Alzheimer’s disease (Polvikoski et al 1995). Another strong support for the amyloid-β
(Aβ) hypothesis, which looks at amyloid-β (Aβ) as the common initiating factor for
Alzheimer's disease, is that transgenic mice solely expressing a mutant human amyloid
precursor protein (APP) gene develop first diffuse and then fibrillar amyloid plaques,
associated with neuronal and microglial damage (Games et al 1995, Masliah et al 1996,
Hsiao et al 1996).

The identification of the amino acid sequence for amyloid-β (Aβ) allowed cloning of its
cognate protein, amyloid precursor protein (APP), and further confirmed it was a type I
membrane protein resembling cell surface receptors. The majority of the current research
is based on the “amyloid cascade hypothesis”. It states that accumulation of amyloid-β
(Aβ) peptide is the initiating event that triggers neuro-degeneration in both sporadic
Alzheimer’s disease cases and familial Alzheimer’s disease cases. The accumulation is
triggered by either overproduction, mutated processing, or mutated clearance of the
amyloid peptide, and consequently leads to self association of amyloid-β (Aβ) as neurotoxic fibrils. In recent years, genetic researches, which aim to link familial Alzheimer’s
disease mutation reported so far to the proteolytic events that generate amyloid-β (Aβ),
further confirm the amyloid-β (Aβ) cascade hypothesis. There are plenty of evidences
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which show that all the amyloid precursor protein (APP) pathogenic mutations are
clustered near the β-secretase and γ-secretase cleavage sites (Evin et al 2002, St GeorgeHyslop 2000). Particularly, presenilin genes that encode essential components of the γsecretase proteolytic complex, have the highest probability of familial Alzheimer’s
disease occurrence rates.

2.2 γ-Secretase
The γ-secretase proteolytic complex consists of four integral membrane proteins, namely
presenilin, nicastrin, APH-1 and PEN-2. Presenilin includes PS1 and PS2 proteins. From
a structural perspective, presenilin contains eight or nine transmembrane domains and
two hypophlic aspartate residues in transmembrane domains which are suggested to form
the catalytic site of the enzymic complex. Nicastrin consists of a single transmembrane
domain and is highly glycosylated in the γ-secretase proteolytic complex. It has been
reported that the DYIGS motif plays an essential role for the recognition of the γsecretase substrates. APH-1 consists of seven transmembrane domains. The homologous
proteins of APH-1a and APH-1b are the typical forms of APH-1 protein. PEN-2 is the
presenilin enhancer, which consists of two transmembrane domains and is an integral
component for the endoproteolysis of presenilin.

APH-1, PEN-2, presenilin, and nicastrin exist in at least three major states during initial
assembly and subsequent maturation of the active γ-secretase proteolytic complex, the
initial unassembled immature components, the immature complex and the mature and
active complex. Biological studies suggest that APH-1 functions as a molecular scaffold
for γ-secretase proteolytic complex. Transition of the immature complex to mature
complex is associated with a presenilin endoproteolysis triggered conformational change.
Motif mutations prevent APH-1 from performing its scaffolding role in initial assembly
of the immature complex. APH-1, PEN-2, presenilin and nicastrin have multiple contacts
with one another.
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2.2.1 Presenilin

Initially found through linkage studies using mutations present in familial Alzheimer’s
cases in 1995 (Sherrington et al 1995), presenilins are a group of related multiple
transmembrane proteins that function as a part of the γ-secretase proteolytic complex.
Vertebrates species have two presenilin genes, namely PSEN1, located on chromosome
14 in humans, that encodes presenilin 1 (PS-1) and PSEN2, on chromosome 1 in humans,
that codes for presenilin 2 (PS-2). Both genes contain conservation among species, with
little difference between rat and human presenilins. The Caenorhabditis elegans has two
genes that represent the presenilins and appear to be functionally similar, sel-12 and hop1 (Smialowska et al 2006).

Figure 3. Presenilin-1 structural model. Presenilins will be cleaved in the
α helical region of one of cytoplasmic loops between transmembrane
domain 6 and transmembrane domain 7 to produce a larger N-terminal and
a smaller C-terminal fragment which will create part of the functional
protein.

Presenilins will be cleaved in the α helical region of one of cytoplasmic loops between
transmembrane domain 6 and transmembrane domain 7 to produce a larger N-terminal
and a smaller C-terminal fragment which will create part of the functional protein.
Cleavage of presenilin 1 can be prevented by a mutation which causes the loss of exon 9,
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and consequently results in loss of functionality. Mutations in the presenilin proteins are
known to cause early onset Alzheimer's disease through mechanisms which are of great
interests to scientists.

Recent research has produced a more widely accepted model with respect to the structure
of presenilin-1. When initially investigated, the presenilin-1 gene was subjected to
hydrophobicity analysis which predicted that the protein would contain ten transmembrane domains. All previous models agreed that the first six putative transmembrane
spanning regions cross the membrane. These regions correspond to the N-terminal
fragment of presenilin-1 but the structure of the C-terminal fragment had been in
investigation for an extended period of time. Due to the nature of presenilin-1with large
numbers of hydrophobic regions, it is inconvenient for x-ray crystallography to determine
a definitive proof of the three dimensional structure.

Generally, speaking, a significant percentage of the cases of Alzheimer's disease are not
hereditary. However, there are a small percentage of cases that have an earlier age of
onset and have a strong genetic influence. From patients of Alzheimer's disease,
mutations in the presenilin proteins either presenilin-1 or presenilin-2 or the amyloid
precursor protein (APP) can be tracked down. A significant percentage of these cases
consists of mutant presenilin genes, either presenilin-1 or presenilin-2. An important part
of the disease pathogenesis in Alzheimer's disease is the accumulation of Amyloid-β (Aβ)
protein. To form Amyloid-β (Aβ) protein, amyloid precursor protein (APP) must be
cleaved by two secretase enzymes, β-secretases and γ-secretase. Presenilin is the
underlying substrate of γ-secretase that is responsible for the cleavage of amyloid
precursor protein (APP) by γ-secretase.
γ-secretase can cleave amyloid precursor protein (APP) at several points within a small
region of the protein which results in Amyloid-β (Aβ) protein of various lengths. The
lengths associated with Alzheimer’s disease are normally 40 and 42 amino acids long.
Aβ-42 is more likely to aggregate to form plaques in the brain than Aβ-40. Presenilin
mutations lead to an increase in the ratio of Aβ-42 produced compared to Aβ-40,
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although the total quantity of Amyloid-β (Aβ) protein produced remains constantly
unchanged (Citron et al 1997, Bentahir et al 2006).

2.2.2 Nicastrin

Figure 4. Nicastrin structural model. Nicastrin is an integral component of
the γ-secretase proteolytic complex involved in processing amyloid
precursor protein (APP) to the Alzheimer's disease associated peptide
Amyloid-β (Aβ) peptides.

Nicastrin, or abbreviated as NCT, is a protein that is an integral component of the γsecretase proteolytic complex, which is one of the proteases involved in processing
amyloid precursor protein (APP) to the Alzheimer's disease associated peptide Amyloidβ (Aβ) peptides. The other proteins involved in the proteolytic complex are presenilin,
which is the catalytically active component of the γ-secretase proteolytic complex, APH1, and PEN-2 (Kaether et al 2006). Nicastrin by itself is not catalytically active, but has
the capacity to promote the maturation and proper trafficking of the other proteins in the
γ-secretase proteolytic complex. All of them will experience significant post-translational
modification before becoming catalytically active in the cell (Zhang et al 2005). Besides
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the role in amyloid precursor protein (APP) pathway, nicastrin has also been identified as
a regulator of neprilysin, an enzyme involved in the degradation of Amyloid-β (Aβ)
protein fragment (Pardossi-Piquard et al 2006).

2.2.3 APH-1

Figure 5. Anterior pharynx-defective 1 structural model. APH-1 is a
protein gene product originally identified in the Notch signaling pathway
in Caenorhabditis elegans as a regulator of the cell surface localization of
nicastrin.

Anterior pharynx-defective 1, or abbreviated as APH-1, is a protein gene product
originally identified in the Notch signaling pathway in Caenorhabditis elegans as a
regulator of the cell surface localization of nicastrin (Goutte et al 2002). APH-1
homologs in other organisms, including humans, have since been identified as
components of the γ-secretase proteolytic complex along with the catalytically active
presenilin and the regulatory nicastrin and PEN-2. The γ-secretase proteolytic complex is
a multimeric protease responsible for the intracellular proteolysis of transmembrane
proteins such as the Notch protein and amyloid precursor protein (APP). γ-secretase
cleavage of amyloid precursor protein (APP) is one of two proteolytic steps necessary to
generate the peptide of Amyloid-β (Aβ). The Amyloid-β (Aβ) misfolded form is
implicated in the pathogenesis of Alzheimer's disease (Kaether et al 2006). All of the
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components of the γ-secretase proteolytic complex experience extensive posttranslational modification, especially proteolytic activation. APH-1 and PEN-2 are
considered as regulators of the maturation process of the catalytic component presenilin
(Luo et al 2003). APH-1 consists of the α helical interaction motif glycine-X-X-Xglycine (GXXXG) that is essential to both assembly of the γ-secretase proteolytic
complex and to the maturation of the components (Lee et al 2004).

2.2.4 PEN-2

Figure 6. Presenilin enhancer 2 structural model. PEN-2 is a protein that
is a regulatory component of the γ-secretase proteolytic complex
responsible for proteolysis of amyloid precursor protein (APP).

Presenilin enhancer 2, abbreviated as PEN-2, is a protein that is a regulatory component
of the γ-secretase proteolytic complex, the one responsible for proteolysis of
transmembrane proteins such as the Notch protein and amyloid precursor protein (APP).
The γ-secretase proteolytic complex consists of PEN-2, APH-1, nicastrin, and the
catalytic subunit presenilin (Kaether et al 2006). PEN-2 is a 101 amino acid integral
membrane protein with a topology structure such that both the N-terminus and the Cterminus face first the lumen of the endoplasmic reticulum (ER) and later the
extracellular environment (Francis et al 2002). Numerous evidences have shown that a
conserved sequence motif D-Y-L-S-F at the C-terminus, as well as the overall length of
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the C-terminal tail, is required for the formation of an active gamma secretase complex
(Hasegawa et al 2004).

2.3 Notch
Discovered in 1917 by Thomas Hunt Morgan when it was first noticed in a strain of the
Drosophila melanogaster, its molecular analysis and sequencing has been widely studied
in the 1980s. The Notch signaling pathway is a highly conserved cell signaling system in
most multicellular organisms. Rather than crossing the membrane multiple passes
between the extracellular and intracellular spaces, the notch receptor is a single-pass
transmembrane receptor protein.

2.3.1 Mechanism
Besides the cleavage role of Amyloid-β (Aβ) peptides formation in γ-secretase
proteolytic complex, presenilins are also implicated in the processing of notch, an
important developmental protein. Mice that have the PS1 gene knocked out die early in
development from developmental abnormalities similar to those found when notch is
disrupted (Shen et al 1997). Together with nicastrin, APH-1 and PEN-2, these four
proteolytic complex is essential for Notch signaling pathway in Caenorhabditis elegans
embryos and is required for intramembrane proteolysis of Notch and β-amyloid precursor
protein in mammalian cells.

The Notch protein sits like a trigger spanning the cell membrane, with part of it inside
and part outside. Ligand proteins binding to the extracellular domain induce proteolytic
cleavage and release of the intracellular domain, which enters the cell nucleus to alter
gene expression.
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2.3.2 Function

The Notch signaling pathway is essential for cell-cell communication. Notch signaling
has also been involved in several processes that control multiple cell differentiation.
Notch signaling is required for physiological angiogenesis and may promote tumor
angiogenesis. A variety of strategies for blocking Notch signaling, in particular γsecretase inhibition, are discussed as potential therapies for breast cancer and tumor
angiogenesis. During the formation of the valve primordial and ventricular development
and differentiation, notch regulates crucial cell communication events between
endocardium and myocardium (Joaquín et al 2007). In the developing cardiac cushion,
Notch signaling plays an essential role in the activity of the cardiac valve homeostasis
and has implications in other human disorders involving the cardiovascular system.
Meanwhile, notch signaling is often repressed in many cancers, and faulty Notch
signaling is implicated in many diseases.

2.3.3 Notch Cascade

Because most ligands are also transmembrane proteins, the receptor is normally only
triggered from direct cell to cell communication. Groups of cells can arrange themselves
in such a way that if one cell expresses a given character, it can be switched off in
neighbor cells by the intercellular Notch signal. This is how the majority of cells
communicate one another to make large structures.

The Notch cascade consists of Notch and Notch ligands, as well as intracellular proteins
transmitting the Notch signal to the cell's nucleus. The Notch receptor family is involved
in the specification of cell fates during development in Drosophila and C. elegans.
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2.4 A Bioinformatic Solution
In the research area of computational biology, sequence alignment is a method to derive
the arrangement of sequences of DNA, RNA and protein sequence on the symbol-wise
base-pair comparison basis so that the maximum similarity between sequences can be
discovered. The biological implication is that we could now identify potential functional,
systematic and phylogenetic relationships between the sequences. Under most
circumstances, a matching equation with some data score value is used to measure how
well two or more residue sequences can be aligned. The matching equation is related to
the total occurrence of mismatch symbols or match symbols either on a percentage basis
or an absolute score value with specific emphasis on special matching or mismatching.
Gaps are defined as the blank spaces inserted between the nucleotide or amino acid
residues to justify or align them with optimal matching score value. There are several
existing approaches to solve either the global sequence alignment or the local sequence
alignment. Theoretically speaking, the comparison between the test sequences and the
sequence corpus database might uncover the potential motifs and domains within the test
sequences. However, numerous evidences indicate there are more complicated
mechanisms behind the wall. A straightforward alignment might not thoroughly reveal
the background information.

Increasing numbers of observations and experiments indicate the inactivation of a certain
gene has no major apparent phenotype and fitness changes of the species. In certain
circumstance, the functionality of a gene can be seen as a replacement of another. The
nature favors the redundancy of the genes. From an engineer's point of view, nature
ensures that the major functionalities are substantially backed up in case of mechanical
failure.

The mutation or deletion of a single gene often has little phenotypic effects due to the
existence of the duplicate genes and the alternative metabolic pathways, regulatory
networks. Particularly, multiple pathways and multiple genes can encode a specific
enzyme in a pathway. In the case of a deletion or mutation of some gene, these
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mechanisms could compensate the loss of the functionality via another copy of the same
genotypic contents. For S. cerevisiae, at least a quarter of those gene deletions that have
no phenotype are compensated by the duplicate genes. The necessity of the duplicate
genes plays an imperative role towards the robustness of the genes against null mutations,
a mutation with no functional change. In Drosophila, seven of the neurogenic phenotype
deletions are extremely similar at the transcription and sequence level sharing the basic
motif of transcriptional regulators. They are non-essentially individually, suggesting the
functional redundancy of the encoded gene products.

Redundancy is wide spread in genomes of higher organisms. They are performing the
same function and the inactivation of one of these genes has little or no effect on the
biological phenotype. They present 4 cases that could explain why the genetic
redundancy is common. A series of evidence show that redundancy itself appears to be a
historical consequence of polyploidy in the vertebrate common ancestor.

2.5 Redundancy and Immunology
Just like redundancy is an imperative element in our routine daily life, it also performs a
substantial role in our human mass body. Numerous evidences indicate that homologous
genes and gene products often have redundant physiological functions. Complement is an
integral part of innate immunity. It functions throughout the body, including the oral
cavity. Complexity and redundancy are important to efficiently kill a wide range of
pathogens, yet not cause destruction of host tissues.

Increasing numbers of observations and experiments indicates the inactivation of a
certain gene has no major apparent phenotype and fitness of the species. In certain
circumstance, the functionality of a gene can be seen as a replacement of another. The
nature favors the redundancy of the genes.
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The wide distributed redundancy of mast cells and macrophage plays an important role in
the inflammation and tumor cytotoxicity. It helps human body to recover from the
bacteria infections. For S. cerevisiae, at least a quarter of those gene deletions that have
no phenotype are compensated by the duplicate genes (Gu et al 2003). The necessity of
the duplicate genes plays an imperative role towards the robustness of the genes against
null mutations, a mutation with no functional change.

Based on the comparative similarity of the induction kinetics of Nur77 and Nor-1 in T
cells, the functional redundancy mechanism of the Nor-1 protein is used to explain the
lack of a phenotype in the Nur77 mutant mice (Cheng et al 1997).

The phenotype of the knock-out mice has been studied by analyzing exhaustively all the
possible genotypic double mutant combinations (Heber et al 2000) so as to link the
relation between complementation and redundancy. They successfully identified the
redundancy between APLP2 , a member of the Amyloid Precursor Protein (APP)
involved in Alzheimer's disease, and both other family members and corroborate a key
physiological role for APLP2. It had been confirmed that the proteins may serve
primarily overlapping functions and complement to each other (Koch et al 1997,
Steinbach et al 1998, White et al 1998).

The mutation or deletion of a single gene often has little phenotypic effects due to the
existence of the duplicate genes and the alternative metabolic pathways, regulatory
networks (Gu et al 2003). Particularly, it has been confirmed that, in Drosophila, seven of
the neurogenic phenotype deletions are extremely similar at the transcription and
sequence level sharing the basic motif of transcriptional regulators (Maier et al 1993).
They are non-essentially individually, suggesting the functional redundancy of the
encoded gene products. A series of evidence has proved that redundancy itself appears to
be a historical consequence of polyploidy in the vertebrate common ancestor (Gibson et
al 1998).
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3. Methodology

3.1 Overview
Alignment of multiple biological sequences is one of the central problems in
computational biology. Multiple sequence alignment has applications in various problems
in biology, and can be applied respectively on DNA, RNA or protein sequences. Example
applications can be found in whole-genome sequencing, identifying conserved regions
and regulatory elements in related genomes, determining important regions for citedirected mutatgenesis, construction of and analysis of phylogenic trees, phylogenic
footprinting, etc. An alignment of the sequences is obtained by inserting gaps at chosen
positions in each of the sequences, such that the resulting sequences all have the same
length. The sequences are thus arranged into an array of symbols, whereby no column is
allowed to contain only gaps. The goodness of an alignment is measured by the
alignment value, which is determined using a scoring function. The problem is therefore
to determine the optimal alignment. A multiple sequence alignment will result in a
minimal alignment value. The result is that the sequences are now arranged such that the
maximal similarity between them are now exposed, and can be exploited for various
applications.

The problem of computing the optimal alignment for multiple sequences is known to be
NP-complete, and thus various heuristics and approximations have been proposed. Most
methods are typically based on either global alignments, or local alignment. Hybrid
approaches aimed at integrating both local and global methods have also been reported.
Example popular alignment programs include CLUSTAL W and its family, T-COFFEE,
DIALIGN and its derivatives, MUSCLE, Align-m, GAME, etc. Gusfield and Mount
provide a detailed discussion on the general problem of sequence alignment.
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We propose a sort based method for constructing multiple sequence alignments. Our
motivation is the recent result in linear time direct suffix sorting, whereby suffix arrays
can be constructed in linear time and space in the worst case, without the need to first
construct suffix trees. This has important implications for both the time required for
computing the alignment, and the space needed for constructing the suffix arrays. We
perform alignment by first identifying a set of anchor points, based on the suffix sorting
output on the sequences. Final alignment and gap considerations can be made by a
recursive application of the sort-based anchor point algorithm.

An important novelty in our approach is how biological mutation information is
incorporated in each refinement step. Thus, the recursive alignment refinement is
performed via sorting and alignment between anchor points using a biological mutated
version of the original sequences. This sort-mutate-anchor paradigm separates our
proposed sequence alignment algorithm from other previously proposed techniques.
In the next section, we briefly describe related work on sequence alignment, with
emphasis on anchor-based methods. The following section presents a brief overview on
linear time direct suffix sorting, the basis of our approach. Our algorithm is presented,
along with an analysis of its results.

3.2 Methods
An approach that has been used to reduce the complexity of multiple sequence alignment
is by the use of selected anchor points along the sequences. An anchor point is defined by
the sequences involved in the anchor, the starting position of the anchor in the sequences,
and the length of the anchor. In some situations, especially with user-defined anchors, the
anchors are given priorities, which can help the algorithm in resolving consistency
between the anchors. Anchor priorities can also be used to determine which anchor points
should be chosen first, where there are multiple anchor points in the same region.
Anchors help to restrict the search required in performing the alignment, by constraining
the required search to only regions between two anchor points. Clearly, the performance
of anchor-based algorithms depends critically on how the anchor points are chosen, and
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to some extent, on how the alignment between anchor points is performed. The sequences
involved in the alignment are represented as horizontal lines. The vertical lines indicate
where an anchor has been established between sequences. Solid vertical lines represent
strong anchors, while the dotted lines depict weak anchors.

Various anchor-based methods have been proposed. The methods differ in the way the
anchor points are defined, in how they are computed, whether or not priorities are
assigned, and in how the remaining sequences between anchors are aligned. The clusters
observed in the sorted common prefix (SCP) data structure were proposed for
determining regions for anchor point computations, using the notion of sphere of
influence for the anchor points.

A maximum unique match (MUM) is a subsequence that occurs only once in each of the
sequences involved in the alignment, and it is not contained in any other MUM. Here, the
MUMs are used to form anchor points for the alignment. The use of MUMs follows the
idea used in popular alignment programs such as BLAST and FASTA. Conceptually, if
there is an MUM between the input sequences, it is most likely to be part of the global
alignment. One problem with MUM-based alignment is that it does not work well in
aligning sequences from relatively distant species. The basic idea has been modified, for
instance, using criteria different from MUMs. Example, GAME used maximal exact
matches (MEMs), rather than MUMs, while in LAGAN, Brudno et al used the idea of
anchors, whereby anchor points are defined based on inexact matches.

In ACANA, anchors are determined by using the edit matrix produced during dynamic
programming. By choosing near-optimal local alignments along the diagonals of the
dynamic programming matrix, they recursively determine the best anchors for global
alignment for each region, which are then fixed for the region. Final alignment is
produced by connecting each region with the fixed anchor points.

Another way to view the anchors is in terms of constraints on the sequences to be aligned.
Such constraints could be user-defined, or could be machine generated based on some
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application dependent information. Myers et al proposed methods for progressive
alignment incorporating sets of constraints, and studied the issue of consistency between
constraints. Brown and Hudek proposed a tree-based method for anchor-based
progressive alignment using spaced or seeded anchors. Spaced anchors are constraints in
the alignment defined in terms of a binary pattern over the sequences, such that matches
or mismatches can be allowed at a given position along the sequences, based on whether
we have say a 1 or 0 at the given position. Sequence alignments using explicit user
defined anchors were studied.

While user-defined constraints can be quite important in some applications, this makes
the methods less flexible, especially in using the algorithms on applications different
from their original purpose. Moreover, for very large sequences, for instance, whole
genomes, or when many sequences are involved, defining these manual anchor points
may become difficult. Automated anchor point determination will thus be needed in such
situations. Such automated methods should be able to provide options for augmenting the
automatically determined anchor points with user-specified anchors. Similar ideas can be
used to incorporate further expertise, for instance, knowledge of locally conserved
protein secondary structures, as constraints in the alignment.

3.2 The Problem and Main Contribution
The computational problem in multiple sequence alignment is often due to the model
used for inducing gaps during the alignment. This is because the optimal alignment often
requires an exhaustive evaluation of all the possibilities for gap insertion in the sequences
being aligned. In fact, from one view point, the problem of sequence alignment can be
viewed as that of appropriate gap induction within the sequences involved. For anchorbased alignment schemes, an additional problem is the selection of anchor points, and the
development of appropriate anchor scoring functions to be used.

The major contribution of this work is a mechanism to cut down on the exhaustive search
required for gap induction. The method we propose is anchor-based, whereby anchors are
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determined based on the sorted suffixes and position-based analysis. In particular, we
propose a sort-based alignment algorithm, using methods of linear-time worst-case suffix
sorting as our basic building block. The sorts implicitly expose where alignments should
be anchored, and which regions are not likely to form an alignment, thereby eliminating
the need for exhaustive gap insertion and alignment score evaluation. We also develop a
new anchor-point evaluation scheme based on the sorted suffixes, position-based sorts,
and a proposed mutation mapping scheme.

After the initial sorting on the original sequences, we extend the sort-based approach
using a novel mutation mapping scheme. Here, symbols are mutated based on a mutation
map derived from standard mutation matrices, and the sorting procedures (suffix sorting
and position-based sorts) on symbols between anchors are now performed on these
mutated symbols. New anchor points are then determined within the previous anchors.
Fixing the anchor points implies that subsequent steps can not change these anchors.
Later alignment steps can only be performed on symbols within the same anchor region.
Operations on symbols in two different anchor regions are forbidden. Sequence
alignment is then performed as a recursive application of this sort-mutate-anchor
paradigm on the symbols between each pair of anchor points.

3.3 Motif Determination
We propose a sort-based multiple sequence alignment algorithm. Based on the
observation that a well matched alignment is also a rearrangement of highly repetitive
segments and non-repetitive region across all the source sequences, the algorithm
transforms the alignment for multiple sequences into a long range repetitive pattern
identification problem where the advantage of the automated suffix sorting technique can
be fully exploited. Since suffix sorting could reveal the repetition information across all
sequences, we can home on the anchor points with the aid of suffix arrays. By
constructing both strong and weak connections, the algorithm builds restraints to cross
and align different sequences by their anchor points. By recursive repetition of the
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procedure using information from biological substitution matrices, the global alignment
for multiple sequences can be obtained.

3.3.1 Overview
We provide a generalized outline of the proposed algorithm. It includes subroutines of the
source sequence concatenation, suffix sorting, anchor points identification and biological
substitution matrices decomposition. The proposed algorithm takes advantage of suffix
sorting by converting inter-sequences vertical alignment problem to one dimension
horizontal repetitive pattern identification using suffix sorting. The general idea is to
concatenate multiple source sequences into a simple sequence with special end-ofsequence symbols, then perform the suffix sorting. This sorting operation exposes the
repetitive segments across the source sequences. We evaluate the suitability of these
repetitive segments for anchor point’s formation by computing their anchor scores. The
segments with anchor scores above a threshold are marked as potential anchor regions.
The starting position of each potential anchor region is a potential anchor point. The
maximum valued anchor points are first selected and fixed onto the blank backbone
sequences. Recursively, a less tightly correlated anchor point identification subroutine is
performed between those previous identified anchor regions until all the anchor regions
are exhausted.

3.3.2 Motif Selection
A one-to-one mapping relation has been noted from the sequence concatenation operation.
The suffix sorting routine is then applied on the simple sequence. This will produce the
suffix which contains all the suffixes, sorted according to their alphabetical orders.
Essentially, input sequence will be partitioned, whereby each group contains suffixes that
start with the identical symbol. This will create the re-sorted motif arrays. Given the oneto-one mapping, each suffix can be marked.

A sliding window is introduced to elaborate the anchor point selection process. The
sliding window is defined as a covered region such that all suffixes fall into this region
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can be factored to determine the anchor point. This region is marked which indicates the
boundary of the potential anchor points. Anchor score for anchor point within the region
Q is computed as shown in the downward sliding. The sliding window is then shifted to
the next suffix by incrementation, namely sliding down the window by one. The new
sliding window covers the region. A similar computation of anchor score can be obtained
as well. The values are listed to the right of each sliding. The anchor score computation
steps are repeated until the sliding window reaches the bottom of each. The algorithm
will proceed to the next group after it finishes the designated group until all groups are
processed. The suffix sorting routine is applied on sequence. Suffix is marked as being
sorted, based on the alphabetical order. Suffix is marked with its corresponding positions.

3.4 Motif Determination with Mutation
One of the disadvantages of direct anchor point sorting is that it only identifies the
strongest anchor points across the source sequences. The implicit structural and
functional significance of biological sequence cannot be fully exploited. We introduce the
biological mutation matrices of BLOSUM and PAM to further refine the multiple
sequence alignment results between two consecutive strong anchor points. These
matrices calculate a log-odds score for all possible substitutions of the $20$ standard
amino acids with typical applications in sequence alignment and multiple sequence
alignment. Both BLOSUM62 and PAM250 are two widely referred biological mutation
matrices. BLOSUM62 is the calculated matrix by using the observed substitutions
between proteins which have 62 or more sequence identity. PAM250 means a 250 point
mutations/100 amino acids which gives the different rates of mutations between pairs of
amino acids.

After obtaining the preliminary results, the mutation-based suffix sort will continue to
further refine the segmental alignment between two consecutive pre-determined anchor
points. The biological mutation matrix will be introduced at this stage. The matrix
denotes the different rates of mutations between pairs of amino acids. Notice the matrix is
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a symmetric matrix. We can group the edges. Because the symmetric property of matrix,
we define the mutation from alphabetically greater symbol to alphabetically smaller. We
define group to contain all mutated vertices where there are parallel edges between each
other. The grouping table is to be used in the mutation-based suffix sorting routine. This
grouping table depends on the biological mutation table only and it is independent of the
input source sequences. The table will be produced once during the alignment procedure.

Because the strong anchor points have been fixed in the first suffix sorting routine, the
mutation based suffix sorting will be applied on the regions between two consecutive
strong anchor points in a decreasing order. The suffix sorting routine is applied on the
regions after each group mutation operation. The mutation information will be written to
a supplemental table in order to recover the mutated sequences back to the origin during
the finalizing steps.

The suffix sorting routine is performed after the mutation. This will anchor the group in
the regions. A suffix sort after the mutation then produces the anchor points.
Continuously performing the mutation, the algorithm will reach a stage when no more
anchor sites can be found to achieve a positive profit gain. At this stage, for any regions
between two adjacent anchor sites, the blank gap spaces are always at the end of the
segment because whenever the algorithm tries to align a local anchor site, it always to
shift the anchor sites to the left and seek fitness and adaptation. Following the mutation
information, the algorithm performs the mutation once for each unique value and stores
the mutation information into the complementary table. The complementary table will be
used to recover the alignment to the original input source sequences after all mutations
have been finished. The mutation is performed in the decreasing order such that the
symbols with stronger affinity will be anchored first.

Each subsequence is recursively aligned within its individual anchor region following the
mutation based suffix sorting routine. After each regional alignment is achieved, they are
concatenated based on the strongest anchor points. The final results are obtained through
concatenation of the regional alignment results from anchor points.
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The traditional bottleneck in alignment is the search for gap positions. Notice that we do
not perform direct search for best positions for gap insertion at each stage. With our
approach to gap induction, it means that the traditional problem of exhaustive search for
nest positions for gap insertion has now been transformed to the problem of searching for
best anchor points. The problem of best positions for gap insertion is handled implicitly
by the sorting stage and the mutation-mapping procedure.

As the sliding window moves along with the anchor sites, some anchor points might be
found to be closer to some previously fixed anchor sites on the consensus sequence. The
proposed algorithm will meet the creation of both anchor sites by insertion of gaps. The
induction of gaps avoids the possibility of assigning two anchor points on the same
location of the consensus sequence. Whenever two anchor points are identified on the
same location of the consensus sequence, the alphabetically smaller anchor point is fixed
at the current location and the alphabetically greater anchor point is fixed at the location
next to the current one to the right. The algorithm fills the corresponding space with gaps
across different sequences.

3.5 Conclusion
We proposed a suffix sorting-based multiple-sequence alignment algorithm with anchor
points. We simplify the alignment score functions so as to better reflect the actual
implication. We analyze the complexity requirements of the proposed algorithm. We
correctly test the proposed algorithm on benchmark sequence data so far. Meanwhile, we
apply the mutation based alignment scheme into the current algorithm. The current
algorithm treats each individual mismatch uniformly. However, we believe that
introducing the mutation mapping will produce a more biologically-relevant alignment.
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4. Motifs of γ-Secretase and Its Substrates
In this study, we employ the designed bioinformatic software packages to study the target
motif substrates of γ-secretase and those relevant domains. As known in most publication,
γ-secretase contains four types of components of Presenilin, APH-1, Pen-2 and Nicastrin.
We apply the sequence scanning technique to all of these four component sets. We
collect the sequence data for the four γ-secretase substrates from NCBI official database.
Mutiple species sequence data are collected to cross examine the target motif substrates
and domain information. Without loss of generality, we take Nicastrin as an example.
Figure 7 is the motif identification results for Nicastrin [Homo Sapiens].

Figure 7. Speculative Motif sites of Nicastrin [Homo Sapiens].

We pass the Nicastrin [Homo Sapiens] to the motif finding program. There are 3 groups,
totalling 5 motifs identified. Three groups include one motif of tyrosine kinase group, one
motif of basophilic serine/threonine kinase group and three motifs of kinase binding site
group. Their gene cards' ID codes are also maintained. Meanwhile, there is one
Nicastrin(196-256) domain associates with the input sequence. Through the sequence
scanning technique, we are able to speculate sets of Nicastrin target motif substrates for
γ-secretase.
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Meanwhile, we also apply the multiple sequence techniques to estimate the Nicastrin
motifs identification. Through this method, we pass the Nicastrin [Homo Sapiens]
domain sequences to the multiple sequence alignments and hidden Markov models
covering many common protein domains and families. We are able to successfully
identify the DYIGS groups, which are reported by the γ-secretase review paper. The
DYIGS groups are marked in blue in the multuple sequence alignment table. Besides that,
we also identify some potential motif sites, as marked in red in the following tables. We
identify E will occur two spaces before DYIGS, forming E-DYIGS pair. E (Glutamic
acid) is then speculated to be located two spaces before DYIGS. Glutamic acid might
play a essential role for the regulatory reactions in γ-secretase target mitifs substrates.
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Table 1. Sequence alignment between Nicastrin [Homo Sapiens] and the other six sets of
Nicastrin variation. DYIGS is reported from our measure as confirmed by the γ-secretase
review paper. Some other similar motif patterns are also reported, which are marked in
red above.
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50
...HKA.PDV
...KQLLPPQ
...SQALP..
...HKA.PDV
...SRV.DGI
...SHL.HDI
TQIEKWQKAS

query_274-499
Q7KS07_DROME_236-469
Q7PY38_ANOGA_276-510
NICA_MOUSE_273-498
NICA_ARATH_251-460
Q6Z743_ORYSA_248-457
NICA_CAEEL_278-508

51
TTLSRNVMFV
SKDLHNVLFV
SND.RNVLFL
TTLSRNVMFV
SNLKKQLVFL
SNLKKQLVFA
NTSNRNVFFA

FFQGETFDYI
TFNGESYDYI
FFNGESYDYI
FFQGETFDYI
VLTGETWGYL
VFNGEAWGYL
FFNGESLDYI

GSSRMVYDME
GSQRFVYDME
GSQRFVYDLQ
GSSRMVYDME
GSRRFLHELD
GSRKFLQELD
GSGAAAYQME

NGKFP.....
KLQFP....T
TGAFP....S
NGKFP.....
LHSDA.....
QGADS.....
NGKFPQMIRS

100
.......VRL
ESTGTPPIAF
RGTQTKPISM
.......VRL
....VAGLSN
....VNGISS
DRTHIHPIRP

query_274-499

101
150
ENIDSFVELG QVALRTSLD. ..LWMHTDPM SQKNESVKNQ VEDLLATLEK
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Q7KS07_DROME_236-469
Q7PY38_ANOGA_276-510
NICA_MOUSE_273-498
NICA_ARATH_251-460
Q6Z743_ORYSA_248-457
NICA_CAEEL_278-508

DNIDFMLDIG
DNIELMIDLG
ENIDSFVELG
TSIETVLEIG
LLIDQVLEIG
NELDYILEVQ

TLDDISN...
ALDNLTD...
QVALRTSLD.
SVGKGLSGGI
SVGKAISQGY
QIGVAKGRK.

..IKLH....
....LHVY..
..LWMHTDPM
NTFFAH....
PLFYAH....
..YYVHVD..

ALNGTTLAQQ
HAAPQPMATK
SQKNESVKNQ
KTRVSSVTNM
AAGNSSISMK
GERYQQNKTQ

ILERLNNYAK
VAELLRKINQ
VEDLLATLEK
TLDALKIAQD
MVDALQSASE
TDRVIDRIER

query_274-499
Q7KS07_DROME_236-469
Q7PY38_ANOGA_276-510
NICA_MOUSE_273-498
NICA_ARATH_251-460
Q6Z743_ORYSA_248-457
NICA_CAEEL_278-508

151
SGAGVPEVVL
SPRYGFNLNI
QFGFGIQAGQ
SGAGVPEVVL
SLASKNIKIL
SLGSDNVKVK
GLRSHAFDLE

RRLAQSQALP
.QSEMSAHLP
PVMTTN..LP
RRLAQSQALP
SADTANPGIP
PAASSNPGVP
KPSGSGDRVP

PSSLQRFLRA
PTSAQSFLRR
PVSAQSFLRE
PSSLQRFLRA
PSSLMAFMRK
PSSLMSFLGK
PASWHSFAKA

R.NISGVVLA
DPNFNALILN
NITFPAVIVA
R.NISGVVLA
NPQTSAVVLE
NSSTPGLVLE
DAHVQSVLLA

200
DHSGSFHNRY
ARPT...NKY
SRPA...NRF
DHSGSFHNRY
DFDTNFVNKF
DFDSQFSNRF
PYGKEYEYQR

query_274-499
Q7KS07_DROME_236-469
Q7PY38_ANOGA_276-510
NICA_MOUSE_273-498
NICA_ARATH_251-460
Q6Z743_ORYSA_248-457
NICA_CAEEL_278-508

201
YQSIYDTAEN
YHSIYDDADN
YHSIYDDQEN
YQSIYDTAEN
YHSHLDDLSN
YHSTLDGPAN
VNSILDKNE.

INVTYPEWQS
VDFTYANTSK
LHYRYGNHSR
INVTYPEWQS
INS.......
VNS.......
..........

..........
..DFTQLTEV
KYDFTQLEDL
..........
..........
..........
..........

...PEEDLNF
N..DFKSLN.
DLGDRSDLYG
...PEEDLNF
..........
..........
...WTEDERE

250
VTDTAKALAN
PDSLQMKVRN
KDSIQMRIRN
VTDTAKALAN
.....SSVVA
.....SSIAA
KAIQEIEAVS

query_274-499
Q7KS07_DROME_236-469
Q7PY38_ANOGA_276-510
NICA_MOUSE_273-498
NICA_ARATH_251-460
Q6Z743_ORYSA_248-457
NICA_CAEEL_278-508

251
VATVLARALY
VSSIVAMALY
ASSLIGMSIY
VATVLARALY
AASVVARTLY
AAALIARSLY
TAILAAAADY

Table 2. Sequence alignment between Nicastrin [Mus musculus] and the other six sets of
Nicastrin variation. DYIGS is reported from our measure as confirmed by the γ-secretase
review paper. Some other similar motif patterns are also reported, which are marked in
red above. "F - - F - G E - - D Y I G S" is speculated as a motif pattern, which might play
an important functional role for "D Y I G S" group. "P P - S - - - F L R" and "N R - Y - S
I - D - - - N" are other possible motif patterns from Nicastrin [Mus musculus].

!!AA_MULTIPLE_ALIGNMENT 1.0
squid.msf MSF: 260 Type: P
Name:
Name:
Name:
Name:
Name:
Name:
Name:

query_284-508
Q7KS07_DROME_236-469
Q7PY38_ANOGA_276-510
NICA_MOUSE_273-498
NICA_ARATH_251-460
Q6Z743_ORYSA_248-457
NICA_CAEEL_278-508

January 28, 2007 02:01
Len:
Len:
Len:
Len:
Len:
Len:
Len:

260
260
260
260
260
260
260

Check:
Check:
Check:
Check:
Check:
Check:
Check:

3143
6993
5861
4890
9664
9567
7440

Check: 7558
Weight:
Weight:
Weight:
Weight:
Weight:
Weight:
Weight:

..

1.00
1.00
1.00
1.00
1.00
1.00
1.00

//

query_284-508
Q7KS07_DROME_236-469
Q7PY38_ANOGA_276-510
NICA_MOUSE_273-498

1
EFIMVATRID
KFILVTCRLD
RIVLVSTRTD
RVVVAATRLD

SHSFFWNIAP
TTTMFDGVGL
TTTMFDGVGL
SRSFFWNVAP

GAESAVSSFV
GAMDSLMGFA
GAMDSVVPFA
GAESAVASFV
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THLAAAEAL.
VFTHVAYLL.
VLVAVAHFL.
TQLAAAEAL.

50
...HKA.SDV
...KQLLPPQ
...SQALP..
...HKA.PDV

NICA_ARATH_251-460
Q6Z743_ORYSA_248-457
NICA_CAEEL_278-508

PVVLTVASMD TASFFRDKSF GADSPISGLV ALLGAVDAL. ...SRV.DGI
PIIMVTASQD SASFFRDRSL GADSPISGLI ALLTAVDAL. ...SHL.HDI
KYMMVTARMD SFGMIPEISV GEVSVLTSII SVLAAARSMG TQIEKWQKAS

query_284-508
Q7KS07_DROME_236-469
Q7PY38_ANOGA_276-510
NICA_MOUSE_273-498
NICA_ARATH_251-460
Q6Z743_ORYSA_248-457
NICA_CAEEL_278-508

51
HLLQRNIMFT
SKDLHNVLFV
SND.RNVLFL
TTLSRNVMFV
SNLKKQLVFL
SNLKKQLVFA
NTSNRNVFFA

FFQGETFDYI
TFNGESYDYI
FFNGESYDYI
FFQGETFDYI
VLTGETWGYL
VFNGEAWGYL
FFNGESLDYI

GSSRMVYDME
GSQRFVYDME
GSQRFVYDLQ
GSSRMVYDME
GSRRFLHELD
GSRKFLQELD
GSGAAAYQME

KDKFP.....
KLQFP....T
TGAFP....S
NGKFP.....
LHSDA.....
QGADS.....
NGKFPQMIRS

100
.......LRL
ESTGTPPIAF
RGTQTKPISM
.......VRL
....VAGLSN
....VNGISS
DRTHIHPIRP

query_284-508
Q7KS07_DROME_236-469
Q7PY38_ANOGA_276-510
NICA_MOUSE_273-498
NICA_ARATH_251-460
Q6Z743_ORYSA_248-457
NICA_CAEEL_278-508

101
ENIHSFVELN
DNIDFMLDIG
DNIELMIDLG
ENIDSFVELG
TSIETVLEIG
LLIDQVLEIG
NELDYILEVQ

QVALRNG...
TLDDISN...
ALDNLTD...
QVALRTSLD.
SVGKGLSGGI
SVGKAISQGY
QIGVAKGRK.

SILWMHTDPV
..IKLH....
....LHVY..
..LWMHTDPM
NTFFAH....
PLFYAH....
..YYVHVD..

SRLNATVEPQ
ALNGTTLAQQ
HAAPQPMATK
SQKNESVKNQ
KTRVSSVTNM
AAGNSSISMK
GERYQQNKTQ

150
VKNLLDILSN
ILERLNNYAK
VAELLRKINQ
VEDLLATLEK
TLDALKIAQD
MVDALQSASE
TDRVIDRIER

query_284-508
Q7KS07_DROME_236-469
Q7PY38_ANOGA_276-510
NICA_MOUSE_273-498
NICA_ARATH_251-460
Q6Z743_ORYSA_248-457
NICA_CAEEL_278-508

151
SSVGANITLQ
SPRYGFNLNI
QFGFGIQAGQ
SGAGVPEVVL
SLASKNIKIL
SLGSDNVKVK
GLRSHAFDLE

.EVGFSQPLP
.QSEMSAHLP
PVMTTN..LP
RRLAQSQALP
SADTANPGIP
PAASSNPGVP
KPSGSGDRVP

PSSFQRFLRA
PTSAQSFLRR
PVSAQSFLRE
PSSLQRFLRA
PSSLMAFMRK
PSSLMSFLGK
PASWHSFAKA

R.HIPGVVLS
DPNFNALILN
NITFPAVIVA
R.NISGVVLA
NPQTSAVVLE
NSSTPGLVLE
DAHVQSVLLA

200
DHQASFQNRY
ARPT...NKY
SRPA...NRF
DHSGSFHNRY
DFDTNFVNKF
DFDSQFSNRF
PYGKEYEYQR

query_284-508
Q7KS07_DROME_236-469
Q7PY38_ANOGA_276-510
NICA_MOUSE_273-498
NICA_ARATH_251-460
Q6Z743_ORYSA_248-457
NICA_CAEEL_278-508

201
YQSMYDTPEN
YHSIYDDADN
YHSIYDDQEN
YQSIYDTAEN
YHSHLDDLSN
YHSTLDGPAN
VNSILDKNE.

IQMQYPEGLS
VDFTYANTSK
LHYRYGNHSR
INVTYPEWQS
INS.......
VNS.......
..........

..........
..DFTQLTEV
KYDFTQLEDL
..........
..........
..........
..........

...PEETLEY
N..DFKSLN.
DLGDRSDLYG
...PEEDLNF
..........
..........
...WTEDERE

250
VTDTAKSLAE
PDSLQMKVRN
KDSIQMRIRN
VTDTAKALAN
.....SSVVA
.....SSIAA
KAIQEIEAVS

query_284-508
Q7KS07_DROME_236-469
Q7PY38_ANOGA_276-510
NICA_MOUSE_273-498
NICA_ARATH_251-460
Q6Z743_ORYSA_248-457
NICA_CAEEL_278-508

251
VATVVARALY
VSSIVAMALY
ASSLIGMSIY
VATVLARALY
AASVVARTLY
AAALIARSLY
TAILAAAADY

Table 3. Sequence alignment between Nicastrin [Gallus gallus] and the other six sets of
Nicastrin variation. DYIGS is reported from our measure as confirmed by the γ-secretase
review paper. Some other similar motif patterns are also reported, which are marked in
red above. "F - - F - G E - - D Y I G S" is speculated as a motif pattern, which might play
an important functional role for "D Y I G S" group. "P P - S - - - F L R" and "N R - Y - S
- - D - - - N" are other possible motif patterns from Nicastrin [Gallus gallus].
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1.00
1.00
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//

query_267-500
Q7KS07_DROME_236-469
Q7PY38_ANOGA_276-510
NICA_MOUSE_273-498
NICA_ARATH_251-460
Q6Z743_ORYSA_248-457
NICA_CAEEL_278-508

1
KFILVTCRLD
KFILVTCRLD
RIVLVSTRTD
RVVVAATRLD
PVVLTVASMD
PIIMVTASQD
KYMMVTARMD

TTTMFDGVGL
TTTMFDGVGL
TTTMFDGVGL
SRSFFWNVAP
TASFFRDKSF
SASFFRDRSL
SFGMIPEISV

GAMDSLMGFA
GAMDSLMGFA
GAMDSVVPFA
GAESAVASFV
GADSPISGLV
GADSPISGLI
GEVSVLTSII

VFTHVAYLL.
VFTHVAYLL.
VLVAVAHFL.
TQLAAAEAL.
ALLGAVDAL.
ALLTAVDAL.
SVLAAARSMG

50
...KQLLPPQ
...KQLLPPQ
...SQALP..
...HKA.PDV
...SRV.DGI
...SHL.HDI
TQIEKWQKAS

query_267-500
Q7KS07_DROME_236-469
Q7PY38_ANOGA_276-510
NICA_MOUSE_273-498
NICA_ARATH_251-460
Q6Z743_ORYSA_248-457
NICA_CAEEL_278-508

51
SKDLHNVLFV
SKDLHNVLFV
SND.RNVLFL
TTLSRNVMFV
SNLKKQLVFL
SNLKKQLVFA
NTSNRNVFFA

TFNGESYDYI
TFNGESYDYI
FFNGESYDYI
FFQGETFDYI
VLTGETWGYL
VFNGEAWGYL
FFNGESLDYI

GSQRFVYDME
GSQRFVYDME
GSQRFVYDLQ
GSSRMVYDME
GSRRFLHELD
GSRKFLQELD
GSGAAAYQME

KLQFP....T
KLQFP....T
TGAFP....S
NGKFP.....
LHSDA.....
QGADS.....
NGKFPQMIRS

100
ESTGTPPIAF
ESTGTPPIAF
RGTQTKPISM
.......VRL
....VAGLSN
....VNGISS
DRTHIHPIRP

query_267-500
Q7KS07_DROME_236-469
Q7PY38_ANOGA_276-510
NICA_MOUSE_273-498
NICA_ARATH_251-460
Q6Z743_ORYSA_248-457
NICA_CAEEL_278-508

101
DNIDFMLDIG
DNIDFMLDIG
DNIELMIDLG
ENIDSFVELG
TSIETVLEIG
LLIDQVLEIG
NELDYILEVQ

TLDDISN...
TLDDISN...
ALDNLTD...
QVALRTSLD.
SVGKGLSGGI
SVGKAISQGY
QIGVAKGRK.

..IKLH....
..IKLH....
....LHVY..
..LWMHTDPM
NTFFAH....
PLFYAH....
..YYVHVD..

ALNGTTLAQQ
ALNGTTLAQQ
HAAPQPMATK
SQKNESVKNQ
KTRVSSVTNM
AAGNSSISMK
GERYQQNKTQ

150
ILERLNNYAK
ILERLNNYAK
VAELLRKINQ
VEDLLATLEK
TLDALKIAQD
MVDALQSASE
TDRVIDRIER

query_267-500
Q7KS07_DROME_236-469
Q7PY38_ANOGA_276-510
NICA_MOUSE_273-498
NICA_ARATH_251-460
Q6Z743_ORYSA_248-457
NICA_CAEEL_278-508

151
SPRYGFNLNI
SPRYGFNLNI
QFGFGIQAGQ
SGAGVPEVVL
SLASKNIKIL
SLGSDNVKVK
GLRSHAFDLE

.QSEMSAHLP
.QSEMSAHLP
PVMTTN..LP
RRLAQSQALP
SADTANPGIP
PAASSNPGVP
KPSGSGDRVP

PTSAQSFLRR
PTSAQSFLRR
PVSAQSFLRE
PSSLQRFLRA
PSSLMAFMRK
PSSLMSFLGK
PASWHSFAKA

DPNFNALILN
DPNFNALILN
NITFPAVIVA
R.NISGVVLA
NPQTSAVVLE
NSSTPGLVLE
DAHVQSVLLA

200
ARPT...NKY
ARPT...NKY
SRPA...NRF
DHSGSFHNRY
DFDTNFVNKF
DFDSQFSNRF
PYGKEYEYQR

query_267-500
Q7KS07_DROME_236-469
Q7PY38_ANOGA_276-510
NICA_MOUSE_273-498
NICA_ARATH_251-460
Q6Z743_ORYSA_248-457
NICA_CAEEL_278-508

201
YHSTYDDADN
YHSIYDDADN
YHSIYDDQEN
YQSIYDTAEN
YHSHLDDLSN
YHSTLDGPAN
VNSILDKNE.

VDFTYANTSK
VDFTYANTSK
LHYRYGNHSR
INVTYPEWQS
INS.......
VNS.......
..........

..DFTQLTEV
..DFTQLTEV
KYDFTQLEDL
..........
..........
..........
..........

N..DFKSLN.
N..DFKSLN.
DLGDRSDLYG
...PEEDLNF
..........
..........
...WTEDERE

250
PDSLQMKVRN
PDSLQMKVRN
KDSIQMRIRN
VTDTAKALAN
.....SSVVA
.....SSIAA
KAIQEIEAVS

query_267-500
Q7KS07_DROME_236-469
Q7PY38_ANOGA_276-510
NICA_MOUSE_273-498
NICA_ARATH_251-460
Q6Z743_ORYSA_248-457
NICA_CAEEL_278-508

251
VSSIVAMALY
VSSIVAMALY
ASSLIGMSIY
VATVLARALY
AASVVARTLY
AAALIARSLY
TAILAAAADY

Table 4. Sequence alignment between Nicastrin [Drosophila melanogaster] and the other
six sets of Nicastrin variation. DYIGS is reported from our measure as confirmed by the
γ-secretase review paper. Some other similar motif patterns are also reported, which are
marked in red above. "F - - F - G E - - D Y I G S" is speculated as a motif pattern, which
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might play an important functional role for "D Y I G S" group. "P P - S - - S F L R" and
"N - - Y H S - - D - - - N" are other possible motif patterns from Nicastrin [Drosophila
melanogaster].
Similar speculation can also be reached following the protocols. The analysis on
Presenilin-1 can have much similar results like Figure 8.

Figure 8. Speculative Motif sites of Presenilin-1 [Homo Sapiens].

The motif pattern identification will be achieved following an automated protocol
specialized to process γ-secretase. Some unprocessed multiple sequence alignment data
are indicated for Presenilin-1. It's straightforward to see that the sliding window method
can help obtain the motif patterns for γ-secretase by measure the short-range repetitious
subsequence segments.
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query_67-455
PSN_CAEEL_38-435
PSN2_RAT_76-439
PSN1_RAT_70-459
PSN_DROME_92-532
HOP1_CAEEL_1-349

1
DEELTLKYGA
VEEAELKYGA
EEELTLKYGA
DEELTLKYGA
EEEQGLKYGA
MPRTKRVYSG

KHVIMLFVPV
SHVIHLFVPV
KHVIMLFVPV
KHVIMLFVPV
QHVIKLFVPV
KTITGVLYPV

TLCMVVVVAT
SLCMALVVFT
TLCMIVVVAT
TLCMVVVVAT
SLCMLVVVAT
AICMLFVAIN
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IKSVSFYTRK
MNTITFYSQN
IKSVRFYTEK
IKSVSFYTRK
INSISFYNST
VKLSQPEQQE

50
DG.QLIYTPF
NGRHLLYTPF
NG.QLIYTPF
DG.QLIYTPF
DV.YLLYTPF
QS.KVVYGLF

SPE4_CAEEL_5-465

RSISSELVRS SQLRWTLFSV IANMSLTLSI WIGVYNMEVN SELSKTYFLD

query_67-455
PSN_CAEEL_38-435
PSN2_RAT_76-439
PSN1_RAT_70-459
PSN_DROME_92-532
HOP1_CAEEL_1-349
SPE4_CAEEL_5-465

51
TEDTETVGQR
VRETDSIVEK
TEDTPSVGQR
TEDTETVGQR
HEQSPEPSVK
HS......YD
PSFEQTTGNL

ALHSILNAAI
GLMSLGNALV
LLNSVLNTLI
ALHSILNAAI
FWSALANSLI
TADSGTITLY
LLDGFINGVG

MISVIVVMTI
MLCVVVLMTV
MISVIVVMTI
MISVIVVMTI
LMSVVVVMTF
LIGFLILTTS
TILVLGCVSF

LLVVLYKYRC
LLIVFYKYKF
FLVVLYKYRC
LLVVLYKYRC
LLIVLYKKRC
LGVFCYQMKF
IMLAFVLFDF

100
YKVIHAWLII
YKLIHGWLIV
YKFIHGWLIM
YKVIHAWLIV
YRIIHGWLIL
YKAIKVYVLA
RRIVKAWLTL

query_67-455
PSN_CAEEL_38-435
PSN2_RAT_76-439
PSN1_RAT_70-459
PSN_DROME_92-532
HOP1_CAEEL_1-349
SPE4_CAEEL_5-465

101
SSLLLLFFFS
SSFLLLFLFT
SSLMLLFLFT
SSLLLLFFFS
SSFMLLFIFT
NSIGILLVYS
SCLLILFGVS

FIYLGEVFKT
TIYVQEVLKS
YIYLGEVFKT
FIYLGEVFKT
YLYLEELLRA
VFHFQRIAEA
AQTLHDMFSQ

YN.......V
FD.......V
YN.......V
YN.......V
YN.......I
QS.......I
VFDQDDNNQY

AVDYITVALL
SPSALLVLFG
AMDYPTLFLA
AVDYITVALL
PMDYPTALLI
PVSVPTFFFL
YMTIVLIVVP

150
IWNFGVVGMI
LGNYGVLGMM
VWNFGAVGMV
IWNFGVVGMI
MWNFGVVGMM
ILQFGGLGIT
TVVYGFGGIY

query_67-455
PSN_CAEEL_38-435
PSN2_RAT_76-439
PSN1_RAT_70-459
PSN_DROME_92-532
HOP1_CAEEL_1-349
SPE4_CAEEL_5-465

151
SIHWKGPLRL
CIHWKGPLRL
CIHWKGPLVL
AIHWKGPLRL
SIHWQGPLRL
CLHWKSHRRL
AFFSNSSLIL

QQAYLIMISA
QQFYLITMSA
QQAYLIVISA
QQAYLIMISA
QQGYLIFVAA
HQFYLIMLAG
HQIFVVTNCS

LMALVFIKYL
LMALVFIKYL
LMALVFIKYL
LMALVFIKYL
LMALVFIKYL
LTAIFILNIL
LISVFYLRVF

PEWTAWLILA
PEWTVWFVLF
PEWSAWVILG
PEWTAWLILA
PEWTAWAVLA
PDWTVWMALT
PSKTTWFVLW

200
VISVYDLVAV
VISVWDLVAV
AISVYDLVAV
VISVYDLVAV
AISIWDLIAV
AISFWDIVAV
IVLFWDLFAV

query_67-455
PSN_CAEEL_38-435
PSN2_RAT_76-439
PSN1_RAT_70-459
PSN_DROME_92-532
HOP1_CAEEL_1-349
SPE4_CAEEL_5-465

201
LCPKGPLRML
LTPKGPLRYL
LCPKGPLRML
LCPKGPLRML
LSPRGPLRIL
LTPCGPLKML
LAPMGPLKKV

VETAQERNET
VETAQERNEP
VETAQERNEP
VETAQERNET
VETAQERNEQ
VETANRRGDD
QEKASDYSKC

LFPALIYSST
IFPALIYSSG
IFPALIYSSA
LFPALIYSST
IFPALIYSST
KFPAILYNSS
VLNLIMFSAN

MVWLVNM...
VIYPYVLVTA
.MVWTVG...
MVWLVNM...
VVYALVNTVT
SYVNEVD...
EKRLTAGSNQ

250
...AEGDPEA
VEN..TTDPR
.....MAK..
...AEGDPEA
PQQSQATASS
......SP..
EETNEGEEST

query_67-455
PSN_CAEEL_38-435
PSN2_RAT_76-439
PSN1_RAT_70-459
PSN_DROME_92-532
HOP1_CAEEL_1-349
SPE4_CAEEL_5-465
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QRRVSK.N..
EPTSSDSN..
....LD....
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SPSSSNST..
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IRRTVKQTIE
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..........
..........
.TTTRATQ..
..........
YYTKREAQDD

..........
.........T
..........
..........
.........N
..........
EFYQKIRQRR

.........S
STAFPGEASC
........PS
.........P
SLASPEAAAA
..........
AAINPDSVPT

300
KYNAE.....
SSETP.....
SQGAL.....
KYSTQ.....
SGQRT.....
..........
EHSPLVEAEP

query_67-455
PSN_CAEEL_38-435
PSN2_RAT_76-439
PSN1_RAT_70-459
PSN_DROME_92-532
HOP1_CAEEL_1-349
SPE4_CAEEL_5-465

301
.STERES.QD
...KRPKVKR
...QLPY...
.GTEREETQD
.....GN.SH
.....SN.ST
SPIELKEKNS

TVAENDDGGF
IPQKVQIESN
DPEMEEDSYD
TGTGSDDGGF
PRQNQRDDGS
PLTEFNNSSS
TEELSDDESD

SEEWE.....
TTAST.....
SFGEP.....
SEEWE.....
VLATEGMPLV
SRLLE.....
TSETS.....

A.........
T.........
S.........
A.........
TFKSNLRGNA
S.........
SGSSNLSSSD

350
......QRDS
......QNSG
..........
......QRDS
EAAGFTQEWS
........DS
SSTTVSTSDI

query_67-455
PSN_CAEEL_38-435
PSN2_RAT_76-439
PSN1_RAT_70-459
PSN_DROME_92-532
HOP1_CAEEL_1-349
SPE4_CAEEL_5-465

351
HLGPHRsTPE
VRVE....RE
..YP....EA
HLGPHRsTPE
ANLS....ER
LLRP....PV
STAE....EC

SRAAVQELSS
LAAERPTVQD
FEAPQPGYP.
SRAAVQELSG
VARRQIEVQS
IPRQIREVR.
DQKEWDDLVS

....SILAG.
....ANFHR.
.........G
....SILTS.
tqsgNAQRSN
..........
....NSLPNN

...ED.....
..HEE.....
EEPEE.....
...ED.....
EYRTVTAPDQ
..........
DKRPATAADA

400
.....PEERG
......EERG
.....EEERG
.....PEERG
NHPDGQEERG
.....EVEGT
L....NDGEV

query_67-455
PSN_CAEEL_38-435
PSN2_RAT_76-439
PSN1_RAT_70-459
PSN_DROME_92-532

401
VKLGLGDFIF
VKLGLGDFIF
VKLGLGDFIF
VKLGLGDFIF
IKLGLGDFIF

YSVLVGKASA
YSVLLGKASS
YSVLVGKAAA
YSVLVGKASA
YSVLVGKASS

TASGDWNTTI
Y..FDWNTTI
TGNGDWSTTL
TASGDWNTTI
Y..GDWTTTI

ACFVAILIGL
ACYVAILIGL
ACFIAILIGL
ACFVAILIGL
ACFVAILIGL

450
CLTLLLLAIF
CFTLVLLAVF
CLTLLLLAVF
CLTLLLLAIF
CLTLLLLAIW

36

HOP1_CAEEL_1-349
SPE4_CAEEL_5-465

IRLGMGDFVF YSLMLGNTVQ T..CPLPTVV ACFVSNLVGL TITLPIVTLS
LRLGFGDFVF YSLLIGQAAA S..GCPFAVI SAALGILFGL VVTLTVFSTE

query_67-455
PSN_CAEEL_38-435
PSN2_RAT_76-439
PSN1_RAT_70-459
PSN_DROME_92-532
HOP1_CAEEL_1-349
SPE4_CAEEL_5-465

451
KKALPALPIS
KRALPALPIS
KKALPALPIS
KKALPALPIS
RKALPALPIS
QTALPALPFP
ESTTPALPLP

ITFGLVFYFA
IFSGLIFYFC
ITFGLIFYFS
ITFGLIFYFA
ITFGLIFCFA
LAIAAIFYFS
VICGTFCYFS

480
TDYLVQPFMD
TRWIITPFVT
TDNLVRPFMD
TDYLVQPFMD
TSAVVKPFME
SHIALTPFTD
SMFFWEQLYG

Table 5. Unprocessed sequence alignment scheme for PSEN1 protein [Homo sapiens]

!!AA_MULTIPLE_ALIGNMENT 1.0
squid.msf MSF: 480 Type: P
Name:
Name:
Name:
Name:
Name:
Name:
Name:

query_43-431
PSN_CAEEL_38-435
PSN2_RAT_76-439
PSN1_RAT_70-459
PSN_DROME_92-532
HOP1_CAEEL_1-349
SPE4_CAEEL_5-465

Len:
Len:
Len:
Len:
Len:
Len:
Len:

January 28, 2007 22:29
480
480
480
480
480
480
480

Check:
Check:
Check:
Check:
Check:
Check:
Check:

8409
8470
7001
744
1070
6457
8805

Check: 956

Weight:
Weight:
Weight:
Weight:
Weight:
Weight:
Weight:

..

1.00
1.00
1.00
1.00
1.00
1.00
1.00

//

query_43-431
PSN_CAEEL_38-435
PSN2_RAT_76-439
PSN1_RAT_70-459
PSN_DROME_92-532
HOP1_CAEEL_1-349
SPE4_CAEEL_5-465

1
DEELTLKYGA
VEEAELKYGA
EEELTLKYGA
DEELTLKYGA
EEEQGLKYGA
MPRTKRVYSG
RSISSELVRS

KHVIMLFIPV
SHVIHLFVPV
KHVIMLFVPV
KHVIMLFVPV
QHVIKLFVPV
KTITGVLYPV
SQLRWTLFSV

TLCMVVVVAT
SLCMALVVFT
TLCMIVVVAT
TLCMVVVVAT
SLCMLVVVAT
AICMLFVAIN
IANMSLTLSI

IKSVSFYTQK
MNTITFYSQN
IKSVRFYTEK
IKSVSFYTRK
INSISFYNST
VKLSQPEQQE
WIGVYNMEVN

50
DGQQLIYTPF
NGRHLLYTPF
NG.QLIYTPF
DG.QLIYTPF
DV.YLLYTPF
QS.KVVYGLF
SELSKTYFLD

query_43-431
PSN_CAEEL_38-435
PSN2_RAT_76-439
PSN1_RAT_70-459
PSN_DROME_92-532
HOP1_CAEEL_1-349
SPE4_CAEEL_5-465

51
REDTETVGQR
VRETDSIVEK
TEDTPSVGQR
TEDTETVGQR
HEQSPEPSVK
HS......YD
PSFEQTTGNL

ALHSMLNAII
GLMSLGNALV
LLNSVLNTLI
ALHSILNAAI
FWSALANSLI
TADSGTITLY
LLDGFINGVG

MISVIVVMTL
MLCVVVLMTV
MISVIVVMTI
MISVIVVMTI
LMSVVVVMTF
LIGFLILTTS
TILVLGCVSF

VLVVLYKYRC
LLIVFYKYKF
FLVVLYKYRC
LLVVLYKYRC
LLIVLYKKRC
LGVFCYQMKF
IMLAFVLFDF

100
YKVIQAWLFF
YKLIHGWLIV
YKFIHGWLIM
YKVIHAWLIV
YRIIHGWLIL
YKAIKVYVLA
RRIVKAWLTL

query_43-431
PSN_CAEEL_38-435
PSN2_RAT_76-439
PSN1_RAT_70-459
PSN_DROME_92-532
HOP1_CAEEL_1-349
SPE4_CAEEL_5-465

101
SNLLLLFFFS
SSFLLLFLFT
SSLMLLFLFT
SSLLLLFFFS
SSFMLLFIFT
NSIGILLVYS
SCLLILFGVS

LIYLGEVFKT
TIYVQEVLKS
YIYLGEVFKT
FIYLGEVFKT
YLYLEELLRA
VFHFQRIAEA
AQTLHDMFSQ

YN.......V
FD.......V
YN.......V
YN.......V
YN.......I
QS.......I
VFDQDDNNQY

AMDYFTLALI
SPSALLVLFG
AMDYPTLFLA
AVDYITVALL
PMDYPTALLI
PVSVPTFFFL
YMTIVLIVVP

150
IWNFGVVGMI
LGNYGVLGMM
VWNFGAVGMV
IWNFGVVGMI
MWNFGVVGMM
ILQFGGLGIT
TVVYGFGGIY

query_43-431
PSN_CAEEL_38-435
PSN2_RAT_76-439
PSN1_RAT_70-459
PSN_DROME_92-532
HOP1_CAEEL_1-349
SPE4_CAEEL_5-465

151
CIHWKGPLRL
CIHWKGPLRL
CIHWKGPLVL
AIHWKGPLRL
SIHWQGPLRL
CLHWKSHRRL
AFFSNSSLIL

QQAYLIMISA
QQFYLITMSA
QQAYLIVISA
QQAYLIMISA
QQGYLIFVAA
HQFYLIMLAG
HQIFVVTNCS

LMALVFIKYL
LMALVFIKYL
LMALVFIKYL
LMALVFIKYL
LMALVFIKYL
LTAIFILNIL
LISVFYLRVF

PEWTAWLILA
PEWTVWFVLF
PEWSAWVILG
PEWTAWLILA
PEWTAWAVLA
PDWTVWMALT
PSKTTWFVLW

200
AISVYDLLAV
VISVWDLVAV
AISVYDLVAV
VISVYDLVAV
AISIWDLIAV
AISFWDIVAV
IVLFWDLFAV

query_43-431
PSN_CAEEL_38-435

201
250
LCPKGPLRIL VETAQERNEA IFPALIYSST MVWLFNM... ADSAETRN..
LTPKGPLRYL VETAQERNEP IFPALIYSSG VIYPYVLVTA VEN..TTDPR

37

PSN2_RAT_76-439
PSN1_RAT_70-459
PSN_DROME_92-532
HOP1_CAEEL_1-349
SPE4_CAEEL_5-465

LCPKGPLRML
LCPKGPLRML
LSPRGPLRIL
LTPCGPLKML
LAPMGPLKKV

VETAQERNEP
VETAQERNET
VETAQERNEQ
VETANRRGDD
QEKASDYSKC

IFPALIYSSA
LFPALIYSST
IFPALIYSST
KFPAILYNSS
VLNLIMFSAN

.MVWTVG...
MVWLVNM...
VVYALVNTVT
SYVNEVD...
EKRLTAGSNQ

.....MAK..
...AEGDPEA
PQQSQATASS
......SP..
EETNEGEEST

query_43-431
PSN_CAEEL_38-435
PSN2_RAT_76-439
PSN1_RAT_70-459
PSN_DROME_92-532
HOP1_CAEEL_1-349
SPE4_CAEEL_5-465

251
..NSSH....
EPTSSDSN..
....LD....
QRRVPK.N..
SPSSSNST..
..DTTR....
IRRTVKQTIE

..........
..........
..........
..........
.TTTRATQ..
..........
YYTKREAQDD

..........
.........T
..........
..........
.........N
..........
EFYQKIRQRR

........PV
STAFPGEASC
........PS
.........P
SLASPEAAAA
..........
AAINPDSVPT

300
PQQEN.....
SSETP.....
SQGAL.....
KYSTQ.....
SGQRT.....
..........
EHSPLVEAEP

query_43-431
PSN_CAEEL_38-435
PSN2_RAT_76-439
PSN1_RAT_70-459
PSN_DROME_92-532
HOP1_CAEEL_1-349
SPE4_CAEEL_5-465

301
...QVAM.AP
...KRPKVKR
...QLPY...
.GTEREETQD
.....GN.SH
.....SN.ST
SPIELKEKNS

TAQPEDDGGF
IPQKVQIESN
DPEMEEDSYD
TGTGSDDGGF
PRQNQRDDGS
PLTEFNNSSS
TEELSDDESD

TPAWV.....
TTAST.....
SFGEP.....
SEEWE.....
VLATEGMPLV
SRLLE.....
TSETS.....

D.........
T.........
S.........
A.........
TFKSNLRGNA
S.........
SGSSNLSSSD

350
......HQQH
......QNSG
..........
......QRDS
EAAGFTQEWS
........DS
SSTTVSTSDI

query_43-431
PSN_CAEEL_38-435
PSN2_RAT_76-439
PSN1_RAT_70-459
PSN_DROME_92-532
HOP1_CAEEL_1-349
SPE4_CAEEL_5-465

351
QLGPMQsTEE
VRVE....RE
..YP....EA
HLGPHRsTPE
ANLS....ER
LLRP....PV
STAE....EC

SRRQIQEMPS
LAAERPTVQD
FEAPQPGYP.
SRAAVQELSG
VARRQIEVQS
IPRQIREVR.
DQKEWDDLVS

....ARPPP.
....ANFHR.
.........G
....SILTS.
tqsgNAQRSN
..........
....NSLPNN

...PA.....
..HEE.....
EEPEE.....
...ED.....
EYRTVTAPDQ
..........
DKRPATAADA

400
...DDDEERG
......EERG
.....EEERG
.....PEERG
NHPDGQEERG
.....EVEGT
L....NDGEV

query_43-431
PSN_CAEEL_38-435
PSN2_RAT_76-439
PSN1_RAT_70-459
PSN_DROME_92-532
HOP1_CAEEL_1-349
SPE4_CAEEL_5-465

401
VKLGLGDFIF
VKLGLGDFIF
VKLGLGDFIF
VKLGLGDFIF
IKLGLGDFIF
IRLGMGDFVF
LRLGFGDFVF

YSMLVGKASA
YSVLLGKASS
YSVLVGKAAA
YSVLVGKASA
YSVLVGKASS
YSLMLGNTVQ
YSLLIGQAAA

TASGDWNTTL
Y..FDWNTTI
TGNGDWSTTL
TASGDWNTTI
Y..GDWTTTI
T..CPLPTVV
S..GCPFAVI

ACFVAILIGL
ACYVAILIGL
ACFIAILIGL
ACFVAILIGL
ACFVAILIGL
ACFVSNLVGL
SAALGILFGL

450
CLTLLLLAIF
CFTLVLLAVF
CLTLLLLAVF
CLTLLLLAIF
CLTLLLLAIW
TITLPIVTLS
VVTLTVFSTE

query_43-431
PSN_CAEEL_38-435
PSN2_RAT_76-439
PSN1_RAT_70-459
PSN_DROME_92-532
HOP1_CAEEL_1-349
SPE4_CAEEL_5-465

451
KKALPALPIS
KRALPALPIS
KKALPALPIS
KKALPALPIS
RKALPALPIS
QTALPALPFP
ESTTPALPLP

ITFGLVFYFA
IFSGLIFYFC
ITFGLIFYFS
ITFGLIFYFA
ITFGLIFCFA
LAIAAIFYFS
VICGTFCYFS

480
TDNLVRPFMD
TRWIITPFVT
TDNLVRPFMD
TDYLVQPFMD
TSAVVKPFME
SHIALTPFTD
SMFFWEQLYG

Table 6. Unprocessed sequence alignment scheme for Psen1 protein [Danio rerio]

!!AA_MULTIPLE_ALIGNMENT 1.0
squid.msf MSF: 480 Type: P
Name:
Name:
Name:
Name:
Name:
Name:
Name:

query_71-459
PSN_CAEEL_38-435
PSN2_RAT_76-439
PSN1_RAT_70-459
PSN_DROME_92-532
HOP1_CAEEL_1-349
SPE4_CAEEL_5-465

Len:
Len:
Len:
Len:
Len:
Len:
Len:

January 28, 2007 22:35
480
480
480
480
480
480
480

Check:
Check:
Check:
Check:
Check:
Check:
Check:

9385
8470
7001
744
1070
6457
8805

//

38

Check: 1932

Weight:
Weight:
Weight:
Weight:
Weight:
Weight:
Weight:

1.00
1.00
1.00
1.00
1.00
1.00
1.00

..

query_71-459
PSN_CAEEL_38-435
PSN2_RAT_76-439
PSN1_RAT_70-459
PSN_DROME_92-532
HOP1_CAEEL_1-349
SPE4_CAEEL_5-465

1
DEELTLKYGA
VEEAELKYGA
EEELTLKYGA
DEELTLKYGA
EEEQGLKYGA
MPRTKRVYSG
RSISSELVRS

KHVIMLFVPV
SHVIHLFVPV
KHVIMLFVPV
KHVIMLFVPV
QHVIKLFVPV
KTITGVLYPV
SQLRWTLFSV

TLCMVVVVAT
SLCMALVVFT
TLCMIVVVAT
TLCMVVVVAT
SLCMLVVVAT
AICMLFVAIN
IANMSLTLSI

IKSVSFYTRK
MNTITFYSQN
IKSVRFYTEK
IKSVSFYTRK
INSISFYNST
VKLSQPEQQE
WIGVYNMEVN

50
DG.QLIYTPF
NGRHLLYTPF
NG.QLIYTPF
DG.QLIYTPF
DV.YLLYTPF
QS.KVVYGLF
SELSKTYFLD

query_71-459
PSN_CAEEL_38-435
PSN2_RAT_76-439
PSN1_RAT_70-459
PSN_DROME_92-532
HOP1_CAEEL_1-349
SPE4_CAEEL_5-465

51
TEDTETVGQR
VRETDSIVEK
TEDTPSVGQR
TEDTETVGQR
HEQSPEPSVK
HS......YD
PSFEQTTGNL

ALHSILNAAI
GLMSLGNALV
LLNSVLNTLI
ALHSILNAAI
FWSALANSLI
TADSGTITLY
LLDGFINGVG

MISVIVIMTI
MLCVVVLMTV
MISVIVVMTI
MISVIVVMTI
LMSVVVVMTF
LIGFLILTTS
TILVLGCVSF

LLVVLYKYRC
LLIVFYKYKF
FLVVLYKYRC
LLVVLYKYRC
LLIVLYKKRC
LGVFCYQMKF
IMLAFVLFDF

100
YKVIHAWLII
YKLIHGWLIV
YKFIHGWLIM
YKVIHAWLIV
YRIIHGWLIL
YKAIKVYVLA
RRIVKAWLTL

query_71-459
PSN_CAEEL_38-435
PSN2_RAT_76-439
PSN1_RAT_70-459
PSN_DROME_92-532
HOP1_CAEEL_1-349
SPE4_CAEEL_5-465

101
SSLLLLFFFS
SSFLLLFLFT
SSLMLLFLFT
SSLLLLFFFS
SSFMLLFIFT
NSIGILLVYS
SCLLILFGVS

FIYLGEVFKT
TIYVQEVLKS
YIYLGEVFKT
FIYLGEVFKT
YLYLEELLRA
VFHFQRIAEA
AQTLHDMFSQ

YN.......V
FD.......V
YN.......V
YN.......V
YN.......I
QS.......I
VFDQDDNNQY

AVDYVTVALL
SPSALLVLFG
AMDYPTLFLA
AVDYITVALL
PMDYPTALLI
PVSVPTFFFL
YMTIVLIVVP

150
IWNFGVVGMI
LGNYGVLGMM
VWNFGAVGMV
IWNFGVVGMI
MWNFGVVGMM
ILQFGGLGIT
TVVYGFGGIY

query_71-459
PSN_CAEEL_38-435
PSN2_RAT_76-439
PSN1_RAT_70-459
PSN_DROME_92-532
HOP1_CAEEL_1-349
SPE4_CAEEL_5-465

151
AIHWKGPLRL
CIHWKGPLRL
CIHWKGPLVL
AIHWKGPLRL
SIHWQGPLRL
CLHWKSHRRL
AFFSNSSLIL

QQAYLIMISA
QQFYLITMSA
QQAYLIVISA
QQAYLIMISA
QQGYLIFVAA
HQFYLIMLAG
HQIFVVTNCS

LMALVFIKYL
LMALVFIKYL
LMALVFIKYL
LMALVFIKYL
LMALVFIKYL
LTAIFILNIL
LISVFYLRVF

PEWTAWLILA
PEWTVWFVLF
PEWSAWVILG
PEWTAWLILA
PEWTAWAVLA
PDWTVWMALT
PSKTTWFVLW

200
VISVYDLVAV
VISVWDLVAV
AISVYDLVAV
VISVYDLVAV
AISIWDLIAV
AISFWDIVAV
IVLFWDLFAV

query_71-459
PSN_CAEEL_38-435
PSN2_RAT_76-439
PSN1_RAT_70-459
PSN_DROME_92-532
HOP1_CAEEL_1-349
SPE4_CAEEL_5-465

201
LCPKGPLRML
LTPKGPLRYL
LCPKGPLRML
LCPKGPLRML
LSPRGPLRIL
LTPCGPLKML
LAPMGPLKKV

VETAQERNET
VETAQERNEP
VETAQERNEP
VETAQERNET
VETAQERNEQ
VETANRRGDD
QEKASDYSKC

LFPALIYSST
IFPALIYSSG
IFPALIYSSA
LFPALIYSST
IFPALIYSST
KFPAILYNSS
VLNLIMFSAN

MVWLVNM...
VIYPYVLVTA
.MVWTVG...
MVWLVNM...
VVYALVNTVT
SYVNEVD...
EKRLTAGSNQ

250
...AEGDPEA
VEN..TTDPR
.....MAK..
...AEGDPEA
PQQSQATASS
......SP..
EETNEGEEST

query_71-459
PSN_CAEEL_38-435
PSN2_RAT_76-439
PSN1_RAT_70-459
PSN_DROME_92-532
HOP1_CAEEL_1-349
SPE4_CAEEL_5-465

251
QRRVPK.N..
EPTSSDSN..
....LD....
QRRVPK.N..
SPSSSNST..
..DTTR....
IRRTVKQTIE

..........
..........
..........
..........
.TTTRATQ..
..........
YYTKREAQDD

..........
.........T
..........
..........
.........N
..........
EFYQKIRQRR

.........P
STAFPGEASC
........PS
.........P
SLASPEAAAA
..........
AAINPDSVPT

300
KYNTQ.....
SSETP.....
SQGAL.....
KYSTQ.....
SGQRT.....
..........
EHSPLVEAEP

query_71-459
PSN_CAEEL_38-435
PSN2_RAT_76-439
PSN1_RAT_70-459
PSN_DROME_92-532
HOP1_CAEEL_1-349
SPE4_CAEEL_5-465

301
.RAERET.QD
...KRPKVKR
...QLPY...
.GTEREETQD
.....GN.SH
.....SN.ST
SPIELKEKNS

SGSGNDDGGF
IPQKVQIESN
DPEMEEDSYD
TGTGSDDGGF
PRQNQRDDGS
PLTEFNNSSS
TEELSDDESD

SEEWE.....
TTAST.....
SFGEP.....
SEEWE.....
VLATEGMPLV
SRLLE.....
TSETS.....

A.........
T.........
S.........
A.........
TFKSNLRGNA
S.........
SGSSNLSSSD

350
......QRDS
......QNSG
..........
......QRDS
EAAGFTQEWS
........DS
SSTTVSTSDI

query_71-459
PSN_CAEEL_38-435
PSN2_RAT_76-439
PSN1_RAT_70-459
PSN_DROME_92-532
HOP1_CAEEL_1-349
SPE4_CAEEL_5-465

351
HLGPHRsTPE
VRVE....RE
..YP....EA
HLGPHRsTPE
ANLS....ER
LLRP....PV
STAE....EC

SRAAVQELSG
LAAERPTVQD
FEAPQPGYP.
SRAAVQELSG
VARRQIEVQS
IPRQIREVR.
DQKEWDDLVS

....SILTS.
....ANFHR.
.........G
....SILTS.
tqsgNAQRSN
..........
....NSLPNN

...ED.....
..HEE.....
EEPEE.....
...ED.....
EYRTVTAPDQ
..........
DKRPATAADA

400
.....PEERG
......EERG
.....EEERG
.....PEERG
NHPDGQEERG
.....EVEGT
L....NDGEV

39

query_71-459
PSN_CAEEL_38-435
PSN2_RAT_76-439
PSN1_RAT_70-459
PSN_DROME_92-532
HOP1_CAEEL_1-349
SPE4_CAEEL_5-465

401
VKLGLGDFIF
VKLGLGDFIF
VKLGLGDFIF
VKLGLGDFIF
IKLGLGDFIF
IRLGMGDFVF
LRLGFGDFVF

YSVLVGKASA
YSVLLGKASS
YSVLVGKAAA
YSVLVGKASA
YSVLVGKASS
YSLMLGNTVQ
YSLLIGQAAA

TASGDWNTTI
Y..FDWNTTI
TGNGDWSTTL
TASGDWNTTI
Y..GDWTTTI
T..CPLPTVV
S..GCPFAVI

query_71-459
PSN_CAEEL_38-435
PSN2_RAT_76-439
PSN1_RAT_70-459
PSN_DROME_92-532
HOP1_CAEEL_1-349
SPE4_CAEEL_5-465

451
KKALPALPIS
KRALPALPIS
KKALPALPIS
KKALPALPIS
RKALPALPIS
QTALPALPFP
ESTTPALPLP

ITFGLVFYFA
IFSGLIFYFC
ITFGLIFYFS
ITFGLIFYFA
ITFGLIFCFA
LAIAAIFYFS
VICGTFCYFS

480
TDYLVQPFMD
TRWIITPFVT
TDNLVRPFMD
TDYLVQPFMD
TSAVVKPFME
SHIALTPFTD
SMFFWEQLYG

ACFVAILIGL
ACYVAILIGL
ACFIAILIGL
ACFVAILIGL
ACFVAILIGL
ACFVSNLVGL
SAALGILFGL

450
CLTLLLLAIF
CFTLVLLAVF
CLTLLLLAVF
CLTLLLLAIF
CLTLLLLAIW
TITLPIVTLS
VVTLTVFSTE

Table 7. Unprocessed sequence alignment scheme for Psen1 protein [Mus musculus]

!!AA_MULTIPLE_ALIGNMENT 1.0
squid.msf MSF: 480 Type: P
Name:
Name:
Name:
Name:
Name:
Name:
Name:

query_65-453
PSN_CAEEL_38-435
PSN2_RAT_76-439
PSN1_RAT_70-459
PSN_DROME_92-532
HOP1_CAEEL_1-349
SPE4_CAEEL_5-465

Len:
Len:
Len:
Len:
Len:
Len:
Len:

January 28, 2007 22:40
480
480
480
480
480
480
480

Check:
Check:
Check:
Check:
Check:
Check:
Check:

1654
8470
7001
744
1070
6457
8805
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Table 8. Unprocessed sequence alignment scheme for Psen1 [Xenopus tropicalis]
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5. Discussion and Conclusion
γ-Secretase is an enzymatic complex which is critical to amyloid formation and other
important pathophysiological processes. Non-specific γ-secretase inhibitors are not ideal
for the intervention of familial Alzheimer’s disease. The four essential inhibitors include
Presenilin (PS1 or PS-2), APH-1, Pen-2, nicastrin (Nct). Also γ-secretase cleaves a
variety of substrates (over 30). But different sites are cleaved even in a single substrate
and no consensus sequence for cleavage by γ-secretase is identified. We predict
consensus structural sequence in components of γ-secretase and its substrates should exist
during γ-secretase regulation and specific γ-secretase inhibitor based on such consensus
may act as a therapeutic intervention for familial Alzheimer’s disease. We accomplish
Stage I and successfully verify Stage II of our initial proposal. We find the candidates by
the comparative methods of bioinformatics. By using the resources of motif identification
and domain prediction databases and tools, selecting software to apply sequence analysis,
modeling and simulation, and pattern recognition of γ-secretase regulation, we find out
the candidates of consensus sequences. We collaborate to use the traditional biological
methods and verify the critical role of the candidates including the protein purification,
recognition, and functional domain interaction.
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